1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Value Added Services in Oncology -- Payer views

Value Added Services in Oncology -- Payer views

  • November 2017
  • ID: 5251963
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

Are your value-added services (VAS) in oncology meeting the needs of payers as well as patients and physicians? Payers are increasingly taking interest in beyond-the-pill services that improve patient adherence, positively impact health outcomes and reduce the overall cost burden. Yet pharma does not consult with payers on VAS development and fails to fully utilise the real world data VAS generates to build evidence of a product’s value. The value of VAS is being recognised by payers and, ultimately, could influence reimbursement and formulary decisions.

This expert report provides a full understanding of what payers would like to see in VAS oncology programmes, the current services they value and what factors pharma should take into account when creating VAS offerings.

Discover on this page...
• Why this report is important to you
• What the report will enable you to do
• DFull Report Contents

Why this report is important to you
Oncology is the most high-profile therapy area with drug innovation delivering significant improvements in outcomes. Yet innovation comes at a cost, and the rising price of oncology drugs and the complexities of managing the disease have led to rising stakeholder expectations about the beyond the pill services industry provides.

Value-added services have traditionally been aimed at patients and physicians, and the payer community has not been involved in the type of VAS being developed. That needs to change. Payers increasingly recognise that VAS can improve patient adherence and clinical outcomes, reduce drug wastage and limit expensive hospital readmissions.

Powerful and engaging VAS not only differentiate products in a competitive market space but may prove advantageous in reimbursement/formulary discussions where VAS outcomes help payers control costs. What VAS motivates payers, how best to develop them and the pitfalls to avoid are all revealed in this expert driven report.

This report will enable you to…
• Understand the specific issues facing VAS planners in the complex cancer therapy area
• Know why long-term VAS programmes are critical in oncology
• Effectively engage with payers to develop VAS that meet their needs
• Know why branded VAS may be working against you
• Mobilise real world data from patient monitoring and engagement to strengthen your value case in a way that is trusted
• Understand how VAS are viewed and used in the US and EU5

Report Contents
Executive summary
Research objectives
Research methodology
Experts interviewed

What are value-added services?
• Key Insights
• Better patient outcomes
• Improved patient education
• Greater patient access
• Opportunities for dialogue with payers
• Considering patient centricity
• The understanding of value-added services
• Working with value-added services
• How would payers rate the eight most common types of value-added service?
• Digital, mobile and telehealth
• Practice and provider support
• Collaborative and integrated care
• Healthcare professional education
• Patient education
• Patient support
• Nursing support
• Health and disease outcomes
• Value-added services not used by experts
• Different uptake of value-added services between countries

What would make a value-added service particularly useful in oncology?
• Key insights
• Application of VAS in chronic diseases and its translation to oncology
• Would this differ for patients, payers or physicians?
• Value-added services outside oncology
• How would value-added services in oncology influence reimbursement decisions?

Specific approaches to oncology value-added services
• Key insights
• Services that help with the complexity of cancer treatment
• Helping patients and families understand cancer and its impact
• Helping patients deal with the complexity of treatment
• Services that treat cancer as a chronic disease
• Services that ensure patients can access high-cost cancer drugs
• Services that support patients with cancer and their families
• Services that support cancer survivors
• Services that educate patients with cancer and their families
• Value-added services within oncology

Payer evaluation: the value of VAS from a payer’s perspective
• Key insights
• How do payers evaluate oncology VAS?
• How is the information communicated?
• Positive or negative impact on outcomes
• What is the most important role of VAS within oncology?
• Are there particular types of drugs or cancers where VAS are most useful/valuable?
• Examples where VAS have improved healthcare systems or increased market access for oncology drugs?
• Have value-added services ever influenced payer decisions?

Learning about VAS
• Key insights
• How do payers hear about oncology VAS?
• How would payers prefer to hear about oncology VAS?
• What information do payers get from pharma in relation to oncology VAS?
• Is the information useful?
• What information are payers not interested in?
• What information is lacking?

What payers want/need from VAS
• Key insights
• What do payers actually want from a VAS for oncology?
• Do payers want branded or drug agnostic services?

VAS and data
• Key insights
• Wearables
• Do certain types of oncology VAS generate more reliable data than others? If so, which types?
• How is RWD influencing assessment of drug value in oncology?

VAS and the pharmaceutical industry
• Key insights
• Are companies consulting with payers about oncology VAS?
• How willing are payers to support pharma in developing oncology VAS?
• Do payers want to work with pharma companies in developing oncology VAS?
• Is pharma being proactive enough with oncology VAS?
• Is pharma understanding payer and patient needs enough?

VAS and the pharmaceutical industry
• Key insights
• The top five challenges presented by VAS in oncology
• What is the future of VAS in oncology?
• What factors should pharma take into consideration when creating VAS offerings?
• What kind of oncology VAS will be beneficial for the healthcare system?
• Could the learning from oncology VAS programmes be applied to other therapeutic areas?

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on